XLRN Pulls The Plug On FSHD Study KPTI Well Funded ACRS Up On Wart Trial Data

XLRN Pulls The Plug On FSHD Study, KPTI Well Funded, ACRS Up On Wart Trial Data

04:09 EDT 17 Sep 2019 | RTTNews

Today's Daily Dose brings you news about Acceleron Pharma pulling the plug on facioscapulohumeral muscular dystrophy trial; Aclaris Therapeutics' THWART-2 trial results; the $150 million investment by HealthCare Royalty Partners in Karyopharm and the upcoming regulatory catalyst of Seattle Genetics.

More From BioPortfolio on "XLRN Pulls The Plug On FSHD Study, KPTI Well Funded, ACRS Up On Wart Trial Data"